We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Valeant Pharmaceuticals announced it has begun enrolling patients in a Phase IIb study of its antiviral compound, taribavirin, an oral nucleoside (guanosine) analog, for the treatment of chronic hepatitis C in conjunction with a pegylated interferon.
Acadia Pharmaceuticals has announced positive top-line results from its Phase II schizophrenia co-therapy trial with ACP-103, its proprietary and selective 5-HT2A inverse agonist.
Cell Therapeutics has filed an application for a special protocol assessment (SPA) with the FDA for the design of its Phase III trial of pixantrone for patients with indolent non- Hodgkin's lymphoma (NHL).
The UK's National Cancer Research Institute has begun a Phase III trial of GV1001, a new immunotherapeutic drug for pancreatic cancer developed by Pharmexa.
AstraZeneca announced that its collaboration partner, AtheroGenics, has revealed first results from the ARISE Phase III clinical trial, which studied AGI-1067, an investigational anti-atherosclerotic agent with antioxidant and anti-inflammatory effects, in patients with coronary artery disease.
Ranbaxy Laboratories announced it has received tentative approval from the FDA to manufacture and market generic zolpidem tartrate tablets, 5 and 10 mg.